Full history for every metric is available with a Kvantra account

Stock profile
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL)

Country: United States of AmericaSector: HealthcareIndustry: Medical - Diagnostics & ResearchExchange: NYSE
P/E TTM
360.4
History
P/E NTM
25.7
Market cap
15.71B
Currency USD
KvantraRankAbout48
IValue28
IIQuality39
IIIMomentum91
Current price
327.93 USD-1.60%
Close 19 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m2,9243,5403,9764,1294,0504,0153,9773,948
Operating profit$m508563
Net profit$m36439148647510-14440565
EPS reported$-2.910.91
Operating cashflow per share$14.8813.02
Capex per share$4.424.66
FCF per share$10.468.36
Free cash flow$m518400
Net debt$m2,3932,243
Book value equity$m3,1653,227
Book value per share$63.8566.42
Number of sharesm49.5648.58
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx-360.36
P/B LTMx3.194.87
P/S LTMx2.513.95
P/FCF LTMx19.4739.32
EV/EBITDA LTMx31.5161.25
EV/Sales LTMx3.224.52
Earnings Yield LTM%-1.43%0.28%
FCF Yield%5.14%2.54%
Quality
ROE%-4.56%1.32%
ROIC%8.36%-3.76%
Operating margin%12.65%14.15%
Gross margin%30.52%32.90%
FCF/Sales%12.91%10.05%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%-0.85%-1.16%
Net Income Growth YoY%--
FCF Growth%+3.37%-26.49%
Operating Profit Growth%+123.38%+299.28%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx0.170.14
Net Debt/EBITDAx6.949.03
EBIT/Net interestx4.745.14
Net debt/market cap%23.71%14.27%
Net debt/Equityx0.760.70
Gross debt/equityx0.970.88

ETFs that hold Charles River Laboratories International

FundTickerPosition#Weight
T. Rowe Price Small-Mid Cap ETFTMSL70.89%
iShares Healthcare Innovation UCITS ETFHEAL.L81.61%
Invesco S&P 500 Equal Weight Health Care ETFRSPH101.81%
UBS MSCI World Small Cap Socially Responsible UCITS ETF USD accWSCSRI.SW70.68%
iShares Morningstar Small Cap Value ETFISCV90.52%
Alpha Architect U.S. Quantitative Momentum ETFQMOM62.43%
Oakmark U.S. Concentrated ETFOAKL104.30%
Research Affiliates Deletions ETFNIXT60.86%

Funds with Charles River Laboratories International among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price327.93 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Websitecriver.com
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Charles River Laboratories International, Inc. (CRL)

CRL · NYSE · Healthcare
327.93 USD-1.60%
Sign up to track this stock
Benchmarks
KvantraRank48
Market cap15.71B
P/E NTM25.7
P/E TTM360.4
KvantraRank?48 / 100
Value
28
Quality
39
Momentum
91
Financialsin USD
20242025TTM2026E
ETFs that hold Charles River Laboratories International
FundTickerPosition#Weight
T. Rowe Price Small-Mid Cap ETFTMSL70.89%
iShares Healthcare Innovation UCITS ETFHEAL.L81.61%
Invesco S&P 500 Equal Weight Health Care ETFRSPH101.81%
UBS MSCI World Small Cap Socially Responsible UCITS ETF USD accWSCSRI.SW70.68%
iShares Morningstar Small Cap Value ETFISCV90.52%
Alpha Architect U.S. Quantitative Momentum ETFQMOM62.43%
Oakmark U.S. Concentrated ETFOAKL104.30%
Research Affiliates Deletions ETFNIXT60.86%

Funds with Charles River Laboratories International among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current327.93 USD
Upside
Price consensus
Last year average price target
Current price327.93 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Websitecriver.com
IndustryMedical - Diagnostics & Research
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free